MA39301A1 - Insuline à action prolongée et utilisation associée - Google Patents

Insuline à action prolongée et utilisation associée

Info

Publication number
MA39301A1
MA39301A1 MA39301A MA39301A MA39301A1 MA 39301 A1 MA39301 A1 MA 39301A1 MA 39301 A MA39301 A MA 39301A MA 39301 A MA39301 A MA 39301A MA 39301 A1 MA39301 A1 MA 39301A1
Authority
MA
Morocco
Prior art keywords
long
insulin
acting insulin
associated use
acting
Prior art date
Application number
MA39301A
Other languages
English (en)
Inventor
Sung Youb Jung
Sang Youn Hwang
Euh Lim Oh
Sung Hee Park
Hyun Uk Kim
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MA39301A1 publication Critical patent/MA39301A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne : un analogue de l'insuline dans lequel la force de liaison au récepteur de l'insuline est réduite afin d'augmenter la demi-vie de l'insuline dans le sang ; une insuline à action prolongée utilisant celui-ci ; un complexe ; et un procédé de préparation de l'insuline à action prolongée.
MA39301A 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée MA39301A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140006938 2014-01-20
PCT/KR2015/000576 WO2015108398A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Publications (1)

Publication Number Publication Date
MA39301A1 true MA39301A1 (fr) 2018-01-31

Family

ID=53543214

Family Applications (3)

Application Number Title Priority Date Filing Date
MA43289A MA43289B1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée
MA46146A MA46146A1 (fr) 2014-01-20 2015-01-20 Insuline a action prolongée et utilisation associée
MA39301A MA39301A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA43289A MA43289B1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée
MA46146A MA46146A1 (fr) 2014-01-20 2015-01-20 Insuline a action prolongée et utilisation associée

Country Status (22)

Country Link
US (1) US10253082B2 (fr)
EP (1) EP3098235A4 (fr)
JP (1) JP2017505141A (fr)
KR (1) KR102406654B1 (fr)
CN (2) CN105916877A (fr)
AU (1) AU2015206890B2 (fr)
BR (1) BR112016016578A2 (fr)
CA (1) CA2937168A1 (fr)
CL (1) CL2016001844A1 (fr)
CR (1) CR20160376A (fr)
DO (1) DOP2016000176A (fr)
EA (1) EA201691374A1 (fr)
EC (1) ECSP16068524A (fr)
IL (1) IL246782B (fr)
MA (3) MA43289B1 (fr)
MX (1) MX369656B (fr)
MY (1) MY186251A (fr)
PE (1) PE20161153A1 (fr)
PH (1) PH12016501414B1 (fr)
SG (1) SG11201605680PA (fr)
WO (1) WO2015108398A1 (fr)
ZA (1) ZA201605626B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9828363B2 (en) 2014-01-20 2017-11-28 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of P97 complex
JP6484337B2 (ja) 2014-11-21 2019-03-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． インスリン受容体部分アゴニスト
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052305A1 (fr) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Procédé de production d'insuline
EP3517544A4 (fr) * 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. Analogue d'insuline ayant une force de liaison réduite au récepteur d'insuline et son utilisation
CN110545849A (zh) * 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
MX2019011297A (es) * 2017-03-23 2019-11-12 Hanmi Pharm Ind Co Ltd Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
JP2020535199A (ja) * 2017-09-29 2020-12-03 ハンミ ファーマシューティカル カンパニー リミテッド 効力が向上した持続性タンパク質結合体
KR102646845B1 (ko) * 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
WO2020120479A1 (fr) 2018-12-11 2020-06-18 Sanofi Liant peptidique
EP4004028A1 (fr) * 2019-07-31 2022-06-01 Eli Lilly and Company Analogues de la relaxine et leurs procédés d'utilisation
IL295826A (en) 2020-03-31 2022-10-01 Hanmi Pharm Ind Co Ltd Novel il-2 analogs that stimulate the immune system

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
CA2356109C (fr) 1999-01-06 2008-04-22 Genentech, Inc. Variants mutants du facteur de croissance insulinomimetique (igf) de type i
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
BRPI0409600A (pt) * 2003-04-29 2006-04-18 Lilly Co Eli análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
PL1648933T3 (pl) 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Długo działające pochodne insuliny i związane z tym sposoby
ES2438098T3 (es) 2003-11-13 2014-01-15 Hanmi Science Co., Ltd. Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
ES2542146T3 (es) * 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
WO2008049711A1 (fr) * 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20100216691A1 (en) 2007-07-16 2010-08-26 Novo Nordisk A/S Protease Stabilized, Pegylated Insulin Analogues
EP2017288A1 (fr) 2007-07-16 2009-01-21 Novo Nordisk A/S Analogues de l'insuline pégylés, stabilisés à la protéase
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2009022005A1 (fr) 2007-08-15 2009-02-19 Novo Nordisk A/S Analogues de l'insuline avec une fraction acyle et alkylène glycol
WO2009063072A2 (fr) 2007-11-16 2009-05-22 Novo Nordisk A/S Composition pharmaceutique contenant de l'insuline et peptide insulinotropique
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
WO2009112583A2 (fr) * 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
DK2910570T3 (en) * 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
WO2009129250A2 (fr) * 2008-04-14 2009-10-22 Case Western Reserve University Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
AU2009305472B2 (en) 2008-10-17 2013-12-19 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
EP2376521B1 (fr) * 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
JP2012521971A (ja) 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
CN103068842B (zh) * 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012015692A2 (fr) 2010-07-28 2012-02-02 Smartcells, Inc. Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci
EP2665487A1 (fr) 2011-01-20 2013-11-27 Zealand Pharma A/S Combinaison d'analogues du glucagon acylé à des analogues d'insuline
MX346488B (es) 2011-03-02 2017-03-22 Oerlikon Surface Solutions Ag Pfäffikon Componente deslizante recubierto con capa de carbono que comprende metal para mejorar el comportamiento de desgaste y de fricción mediante las aplicaciones tribológicas bajo las condiciones lubricadas.
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
RU2578641C2 (ru) 2011-05-03 2016-03-27 Тейджин Арамид Б.В. Пуленепробиваемая панель
BR112013030933A2 (pt) 2011-06-02 2018-04-24 Prolor Biotech Inc agonistas do receptor de glp-1/glucágon de ação prolongada
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN103732618B (zh) 2011-06-10 2018-10-09 韩美科学株式会社 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
WO2013089463A1 (fr) 2011-12-16 2013-06-20 Lg Innotek Co., Ltd. Procédé de dépôt de carbure de silicium et tranche épitaxiale de carbure de silicium
WO2013110069A1 (fr) 2012-01-20 2013-07-25 Case Western Reserve University Analogues de l'insuline stabilisés par l'acide glutamique
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014049610A2 (fr) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
MY197849A (en) 2012-11-06 2023-07-20 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
ES2868351T3 (es) * 2013-02-26 2021-10-21 Hanmi Pharm Ind Co Ltd Conjugados de análogos de insulina y usos de los mismos
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도

Also Published As

Publication number Publication date
AU2015206890A1 (en) 2016-08-04
BR112016016578A2 (pt) 2017-10-03
ZA201605626B (en) 2017-11-29
IL246782B (en) 2020-01-30
KR102406654B1 (ko) 2022-06-10
DOP2016000176A (es) 2017-02-15
CL2016001844A1 (es) 2017-01-06
EP3098235A4 (fr) 2017-10-18
MX369656B (es) 2019-11-15
WO2015108398A1 (fr) 2015-07-23
PH12016501414A1 (en) 2016-09-14
MY186251A (en) 2021-06-30
JP2017505141A (ja) 2017-02-16
MA46146A1 (fr) 2020-12-31
CR20160376A (es) 2016-10-07
EA201691374A1 (ru) 2016-12-30
CN116987172A (zh) 2023-11-03
PH12016501414B1 (en) 2016-09-14
ECSP16068524A (es) 2018-11-30
PE20161153A1 (es) 2016-10-27
MA43289B1 (fr) 2019-12-31
US20170101455A1 (en) 2017-04-13
EP3098235A1 (fr) 2016-11-30
AU2015206890B2 (en) 2019-05-23
MX2016009434A (es) 2017-01-18
KR20150087130A (ko) 2015-07-29
US10253082B2 (en) 2019-04-09
SG11201605680PA (en) 2016-09-29
CN105916877A (zh) 2016-08-31
IL246782A0 (en) 2016-08-31
CA2937168A1 (fr) 2015-07-23

Similar Documents

Publication Publication Date Title
MA39301A1 (fr) Insuline à action prolongée et utilisation associée
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
EA201590058A1 (ru) Аналоги глюкагона
EP4238496A3 (fr) Systèmes et procédés de capteur d'analyte transcutané
AR102712A1 (es) Agonistas parciales del receptor de insulina
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
SA518400491B1 (ar) نظير إنسولين جديد واستخدامه
TWD176317S (zh) 手錶
BR112016023948A2 (pt) proteínas fc multiméricas
MX2016016868A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
CO2019007846A2 (es) Proteínas de unión al antígeno anti-neuropilina y sus métodos de uso
TWD170984S (zh) 手錶
TWD175721S (zh) 手錶
EA201890584A1 (ru) Новые аналоги инсулина и их применение
MD3258919T3 (ro) Formulare de pulbere nazală pentru tratamentul hipoglicemiei
CO2019006424A2 (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas
TWD179450S (zh) 手錶
MX2013013918A (es) Estructura de activacion de aplicacion.
TWD166474S (zh) 手錶
BR112015023672A2 (pt) análogo de insulina, orto-fluoro, sequência de dna codificando a cadeia a de análogo de insulina, sequência de dna codificando a cadeia b de análogo de insulina e uso de um análogo de insulina.
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
TWD179291S (zh) 座標輸入器之部分
GB2535410A (en) Portable securing device
EA201690766A1 (ru) Растворимый fc-гамма рецептор для лечения аутоиммунных буллезных заболеваний